On June 7th, 2021, the US FDA (Food and Drug Administration) approved aducanumab (brand name: Aduhelm), introducing the first new drug for Alzheimer’s disease in nearly two decades. This approval has created a great deal of excitement for the millions of patients and families living with Alzheimer’s disease. It has also raised many questions for patients, families and providers.more»
New York (Jan. 19, 2021) —The American Geriatrics Society (AGS) launched its new AGS Cognitive Screening Toolkit on the iGeriatrics app today, introducing an easy-to-access resource that can help clinicians select the appropriate free, open-access cognitive screening test among those identified by the U.S. Preventive Services Task Force (USPSTF) for use with primary care patients.
Users can browse each of the 10 free cognitive screening tests or narrow their choices using filters based on how the test is administered: whether it evaluates a patient's executive function and/or short-term memory; whether it is simple or challenging to score; and whether it takes less or more than 10 minutes to complete.more»
The American Association for Geriatric Psychiatry (AAGP) is a diverse, national organization of more than 1300 health professionals, scientists, and advocates committed to reducing mental suffering and promoting emotional and cognitive health in all older adults regardless of race, gender, ethnicity, sexual orientation, or faith community…To read the entire statement, click here.more»
Wednesday, Aug. 29, 2018, AKRON: Cleveland Clinic Akron General recently appointed Rajesh R. Tampi, M.D., MS, DFAPA, as the new chair of the Department of Psychiatry and Psychology. Dr. Tampi, a resident of Strongsville, will also lead the section of Geriatric Psychiatry for the Department of Psychiatry and Psychology at Cleveland Clinic.more»
Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). TRINTELLIX is the first FDA-approved treatment for MDD where the U.S. labelling now includes data from the largest replicated clinical studies on an important aspect of cognitive function in acute major depressive disorder (MDD, depression). The FOCUS and CONNECT studies showed TRINTELLIX had a positive effect on processing speed, an important aspect of cognitive function that may be impaired in adult patients with acute MDD.more»
Dr. Hugh C. Hendrie was awarded the 2017 Lifetime Achievement Award in London on July 16, 2017 at the 2017 Alzheimer's Association International Conference. Click here to view press release from the Alzhemier's Association.more»